國家衛生研究院 NHRI:Item 3990099045/15963
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 909678      線上人數 : 835
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15963


    題名: Cancer and pulmonary fibrosis risks in patients with dermatomyositis and polymyositis: A retrospective cohort study
    作者: Sung, FC;Chen, PC;Muo, CH;Shen, TC;Gerbino, AJ
    貢獻者: National Center for Geriatrics and Welfare Research
    摘要: Background: This study assessed the risks of developing pulmonary fibrosis and cancer and whether patients are at risk of acquiring subsequent cancer after pulmonary fibrosis development. Methods: From the claims data of 22 million insured people, we identified 1461 patients with dermatomyositis (DM) and 1058 with polymyositis (PM) diagnosed in 1996 -2016 and 50,380 comparison individuals without pulmonary fibrosis and cancer at baseline, matched by sex and age. Incident pulmonary fibrosis and cancer in each cohort were assessed at the end of 2016. We further followed up individuals with and without pulmonary fibrosis to assess the subsequent development of cancer. Results: The cancer incidence was 2.6-fold higher in the DM/PM groups combined than in comparisons (135.3 vs. 52.1 per 10,000 person-years), with an adjusted hazard ratio (aHR) of 3.11 (95 % confidence interval [CI] = 2.71 -3.58). The incidence was lower in patients with PM than in those with DM (81.3 vs. 176 per 10,000 person-years), with an aHR of 0.39 (95 % CI = 0.29 -0.54). The likelihood of developing pulmonary fibrosis was 92 times higher in the PM/DM groups combined than in comparisons (37.9 vs. 0.41 per 10,000 person-years; aHR 84.0 (95 % CI = 49.5 -143). The incidence was 1.44-fold higher in patients with PM than in those with DM (46.1 vs. 32.0 per 10,000 person-years), but the difference was not significant. Further analysis showed that in 2452 patients with myositis without pulmonary fibrosis, 234 (9.5 %) had cancer, whereas no cancer was identified in 67 patients with pulmonary fibrosis ( p = 0.019). Conclusion: Patients with PM and DM are at great risk of developing cancer and pulmonary fibrosis. Patients who develop pulmonary fibrosis might be at low risk of developing cancer. The complexity of cancer risk interplaying between patients with and without pulmonary fibrosis has clinical relevance and deserves further investigation. Patients who are free of pulmonary fibrosis deserve close monitoring to reduce subsequent cancer risk.
    日期: 2024-07-15
    關聯: Heliyon. 2024 Jul 15;10(13):Article number e33883.
    Link to: http://dx.doi.org/10.1016/j.heliyon.2024.e33883
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2405-8440&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001265916500001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85197396237
    顯示於類別:[陳培君] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI001265916500001.pdf1023KbAdobe PDF44檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋